A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)

NCT04657497 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection (COVID-19)

Interventions

DRUG: FOY-305
DRUG: Placebo

Sponsor

Ono Pharmaceutical Co., Ltd.